- Practice-changing results of T-DXd in HER2-low breast cancer Trastuzumab deruxtecan (T-DXd) outperformed therapy by physician’s choice in patients with HER2-low unresectable or metastatic breast cancer who had received 1 or 2 previous lines of chemotherapy. T-DXd is the first HER2-targeted therapy to outperform the standard-of-care in terms of progression-free survival and overall survival in the hard-to-treat HER2-low breast cancer population.
- Spectacular results for dostarlimab in mismatch repair deficient rectal cancer A phase 2 trial, investigating neoadjuvant treatment with the PD-1 inhibitor dostarlimab in patients with stage II or III mismatch repair deficient rectal cancer showed a response rate of 100% following treatment with this agent in the thus far analysed patients. Off-protocol use of neoadjuvant immunotherapy in this population is likely to occur.
- Ifosfamide is likely to be the go-to-therapy in recurrent Ewing sarcoma Ifosfamide was more efficacious than topotecan plus cyclophosphamide in patients with primary recurrent or refractory Ewing sarcoma, despite a higher discontinuation rate due to toxicity in the ifosfamide arm. The phase 3 rEECur trial is the first randomised study to deliver efficacy, safety, and quality-of-life data to inform physicians on chemotherapy treatment decisions for patients with recurrent Ewing sarcoma.
- Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma The non-chemotherapeutic combination of dabrafenib and trametinib outperformed standard-of-care chemotherapy in paediatric patients with BRAF V600-mutated low-grade glioma. With the manageable safety profile, it shows potential as a new standard-of-care for this population.
- New standard-of-care for cisplatin-ineligible LAHNSCC Docetaxel added to radiation improved the disease-free survival (DFS) and overall survival (OS) of patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current randomised trial is the first study to assess docetaxel as a radiosensitiser in cisplatin-ineligible patients with LAHNSCC and resulted in the presentation of a new reference standard-of-care for this population.
- Panitumumab beats bevacizumab in RAS wild-type left-sided metastatic colorectal cancer Panitumumab was superior to bevacizumab when added to mFOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC), especially in patients with left-sided tumours. The results of the phase 3 PARADIGM trial support mFOLFOX6 plus panitumumab as first-line therapy in patients with RAS wild-type left-sided mCRC.
Table of Contents: ASCO 2022
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.